
CLAIMS

1. A nitrogen-containing compound of formula **I**, an isotope-labeled compound thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of the pharmaceutically acceptable salt thereof;



I

wherein

X^1, X^2, and X^3 are each independently selected from CH and N;


R^1, R^2, R^3, R^4, and R^5 are each independently selected from hydrogen and deuterium;

R^6 is $-(CH_2)_nR^7$;

n is 0, 1, 2, or 3;

R^7 is selected from C1-C6 alkyl, deuterated C1-C6 alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl.

2. The compound of formula **I**, the isotope-labeled compound thereof, the solvate thereof, the pharmaceutically acceptable salt thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound of formula **I** is represented by formula **Ia**;



Ia

3. The compound of formula **I**, the isotope-labeled compound thereof, the solvate thereof, the pharmaceutically acceptable salt thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 1, wherein

X^1 is N; X^2 is CH or N; X^3 is CH;

or, X^1 is N; X^2 and X^3 are CH.

4. The compound of formula **I**, the isotope-labeled compound thereof, the solvate thereof, the pharmaceutically acceptable salt thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 1, wherein

R^6 is $-(CH_2)_nR^7$;

n is 0 or 1;

R^7 is selected from C1-C3 alkyl, deuterated C1-C3 alkyl, C1-C3 haloalkyl, and C3-C6 cycloalkyl.

5. The compound of formula **I**, the isotope-labeled compound thereof, the solvate thereof, the pharmaceutically acceptable salt thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 1, wherein

R^6 is $-(CH_2)_nR^7$;

n is 0 or 1;


R^7 is selected from $-CH_3$, $-CD_3$, $-CF_3$, and cyclopropyl.

6. The compound of formula **I**, the isotope-labeled compound thereof, the solvate thereof, the pharmaceutically acceptable salt thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 1, wherein


R^1, R^2, and R^3 are deuterium; R^4 and R^5 are hydrogen;

or, R^1, R^2, and R^3 are hydrogen; R^4 and R^5 are deuterium.

7. The compound of formula **I**, the isotope-labeled compound thereof, the solvate thereof, the pharmaceutically acceptable salt thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 1, wherein formula **I** is formula **Ib** or **Ic**;






Ib



Ic

;

wherein in formulas **Ib** and **Ic**,  is  or  ;


R^1, R^2, R^3, R^4, and R^5 are each independently selected from hydrogen and deuterium;

R^6 is $-(CH_2)_nR^7$;

n is 0 or 1;

R^7 is selected from C1-C6 alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl.


8. The compound of formula **I**, the isotope-labeled compound thereof, the solvate thereof, the pharmaceutically acceptable salt thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 7, wherein



















in formulas **Ib** and **Ic**,  is selected from $-OCH_3$ and $-OCD_3$;


R^4 and R^5 are selected from hydrogen;











R^6 is $-(CH_2)_nR^7$; n is 0 or 1; R^7 is selected from $-CH_3$, $-CD_3$, $-CF_3$, and cyclopropyl.

9. The compound of formula **I**, the isotope-labeled compound thereof, the solvate thereof, the pharmaceutically acceptable salt thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound of formula **I** is selected from the following compounds:




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

and

, an enantiomer thereof, or a mixture of the two in any ratio.

10. A pharmaceutical composition comprising the compound of formula **I**, the isotope-labeled compound thereof, the solvate thereof, the pharmaceutically acceptable salt thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 1, and a pharmaceutical excipient.


11. Use of the compound of formula **I**, the isotope-labeled compound thereof, the solvate thereof, the pharmaceutically acceptable salt thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 1 in the manufacture of a medicament for promoting

the binding of p53 Y220C mutants with DNA.

12. Use of the pharmaceutical composition according to claim 10 in the manufacture of a medicament for promoting the binding of p53 Y220C mutants with DNA.

13. Use of the compound of formula **I**, the isotope-labeled compound thereof, the solvate thereof, the pharmaceutically acceptable salt thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 1 in the manufacture of a medicament for the treatment of gastric cancer.

14. A compound of formula **a-11** or **a-32**;



a-11 a-33

wherein X is halogen; R^8 is an amino protecting group;

X^1, X^2, and X^3 are each independently selected from CH and N;




R^1, R^2 and R^3 are each independently selected from hydrogen and deuterium;



R^6 is $-(CH_2)_nR^7$;

n is 0, 1, 2, or 3;

R^7 is selected from C1-C6 alkyl, deuterated C1-C6 alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl.

15. The compound of formula **a-11** or **a-32** according to claim 14, wherein the compound of formula **a-11** or **a-32** is any one of the following compounds;

, , ,

 or .